Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation

被引:47
作者
Speich, R [1 ]
Thurnheer, R
Gaspert, A
Weder, W
Boehler, A
机构
[1] Univ Zurich Hosp, Dept Internal Med, Med Clin A, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Surg, CH-8091 Zurich, Switzerland
关键词
D O I
10.1097/00007890-199901270-00023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Cytomegalovirus is the single most frequent pulmonary pathogen in lung transplant recipients who survive at least 2 weeks. Patients at increased risk are either seropositive or have received an allograft from a donor with latent infection. Morbidity and mortality caused by cytomegalovirus dis ease is still considerably high. Methods. In an open, comparative study, we evaluated the efficacy, tolerance, and cost effectiveness of postoperative ganciclovir prophylaxis: intravenous dose of 2x5 mg/kg/day for 14 days, followed by either intravenous doses of 5 mg/kg/day (five patients), or oral doses of 3 x 1000 mg (nine patients) up to 90 days. Oral ganciclovir was continued until prednisone was tapered below 15 mg/day, Prophylaxed groups were compared with a historical control (eight patients) in respect to cytomegalovirus disease, in-hospital stay, overall costs, and survival. Follow-up times and the net state of immunosuppressive therapy between groups were comparable. Results. Six (75%) of the non-prophylaxed patients developed cytomegalovirus disease compared to none in the intravenous and one in the oral ganciclovir group (P=0.013). The non-prophylaxed patients had a longer cytomegalovirus-related in-hospital stay (P=0.018) and nonsignificantly higher cytomegalovirus-related costs. Bronchiolitis obliterans syndrome was less frequent with prophylaxis (P=0.039), and survival tended to be better (P=0.072). The only adverse effect was a subclavian vein thrombosis in the intravenous ganciclovir group. Conclusions. In lung transplant recipients, ganciclovir prophylaxis, either intravenous or oral, is safe, well tolerated, and effective in preventing cytomegalovirus disease. Moreover, ganciclovir prophylaxis seems likely to reduce the incidence of bronchiolitis obliterans syndrome. The oral formulation might be preferable because its convenience and possibly lower costs.
引用
收藏
页码:315 / 320
页数:6
相关论文
共 28 条
[1]   FAILURE OF PROPHYLACTIC GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF LUNG TRANSPLANTS [J].
BAILEY, TC ;
TRULOCK, EP ;
ETTINGER, NA ;
STORCH, GA ;
COOPER, JD ;
POWDERLY, WG .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (03) :548-552
[2]   A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS [J].
BALFOUR, HH ;
CHACE, BA ;
STAPLETON, JT ;
SIMMONS, RL ;
FRYD, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) :1381-1387
[3]   LIMITATIONS OF SPIROMETRY IN DETECTING REJECTION AFTER SINGLE-LUNG TRANSPLANTATION [J].
BECKER, FS ;
MARTINEZ, FJ ;
BRUNSTING, LA ;
DEEB, GM ;
FLINT, A ;
LYNCH, JP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (01) :159-166
[4]   Prospective study of the value of transbronchial lung biopsy after lung transplantation [J].
Boehler, A ;
Vogt, P ;
Zollinger, A ;
Weder, W ;
Speich, R .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (04) :658-662
[5]  
COOPER JD, 1993, J HEART LUNG TRANSPL, V12, P713
[6]   Drug therapy - Ganciclovir [J].
Crumpacker, CS .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :721-729
[7]  
DUNCAN AJ, 1991, J HEART LUNG TRANSPL, V10, P638
[8]   SEQUELAE OF CYTOMEGALOVIRUS PULMONARY INFECTIONS IN LUNG ALLOGRAFT RECIPIENTS [J].
DUNCAN, SR ;
PARADIS, IL ;
YOUSEM, SA ;
SIMILO, SL ;
GRGURICH, WF ;
WILLIAMS, PA ;
DAUBER, JH ;
GRIFFITH, BP .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (06) :1419-1425
[9]   GANCICLOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTIONS IN PULMONARY ALLOGRAFT RECIPIENTS [J].
DUNCAN, SR ;
PARADIS, IL ;
DAUBER, JH ;
YOUSEM, SA ;
HARDESTY, RL ;
GRIFFITH, BP .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (05) :1213-1215
[10]   A COMPARISON OF GANCICLOVIR AND ACYCLOVIR TO PREVENT CYTOMEGALOVIRUS AFTER LUNG TRANSPLANTATION [J].
DUNCAN, SR ;
GRGURICH, WF ;
IACONO, AT ;
BURCKART, GJ ;
YOUSEM, SA ;
PARADIS, IL ;
WILLIAMS, PA ;
JOHNSON, BA ;
GRIFFITH, BP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (01) :146-152